Cancer cachexia robs patients of weight, muscle, and strength, undermining treatment success and quality of life. Experts now advocate for a multimodal approach—combining nutrition, exercise, and ...

A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently incurable and can be life-threatening. Detecting and intervening early can ...

CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of ...

University of Oklahoma researcher Min Li, Ph.D., is the lead author of a new publication in Cancer Cell about cancer cachexia. Cachexia is a muscle-wasting and fat-loss condition that most often ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most serious and underserved supportive-care markets The ...

Trial will evaluate visugromab's potential to reverse cancer-associated weight loss and muscle wasting by targeting GDF-15 in patients with advanced solid tumors Fourth Phase 2b study of visugromab ...